Christine Chung L.
Corporate Officer/Principal at FIBROGEN, INC.
Net worth: 209 460 $ as of 2024-04-29
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| James Schoeneck | M | 66 | 14 years | |
| Thane Wettig | M | 59 | 4 years | |
| Jeffrey Edwards | M | 64 | 9 years | |
| Michael D. Lowenstein | M | - |
FibroGen (China) Medical Technology Development Co. Ltd.
 FibroGen (China) Medical Technology Development Co. Ltd. Pharmaceuticals: MajorHealth Technology Part of FibroGen, Inc., FibroGen (China) Medical Technology Development Co., Ltd. is a biomedical technology company based in Beijing, China. FibroGen () is dedicated to developing new mechanisms of action or "best-in-class" innovative drugs and medical devices to meet the unmet clinical needs of Chinese patients. The Chinese company also provides a platform to report adverse events related to FibroGen roxadustat products. The company was founded in 2011. Christine Chung L. has been the CEO of the company since 2019. | 21 years |
| Meichiel Keenan | F | - | 20 years | |
| Jeffrey Henderson | M | 59 | 9 years | |
| Suzanne Blaug | F | 66 | 5 years | |
| Aoife Brennan | M | 48 | 4 years | |
| May Kin Ho | M | 71 | 6 years | |
| Gerald Lema | M | 63 | 7 years | |
| Benjamin Cravatt | M | 54 | 4 years | |
| Al Y. Lin | M | - | 25 years | |
| Ai Min Fu | M | - |
Beijing Falikang Pharmaceutical Co. Ltd.
 Beijing Falikang Pharmaceutical Co. Ltd. Pharmaceuticals: MajorHealth Technology Part of FibroGen, Inc., Beijing Falikang Pharmaceutical Co. Ltd. is a pharmaceutical company that manufactures pharmaceutical products. Beijing Falikang Pharmaceutical Co. Ltd. is based in Beijing, China. Beijing Falikang Pharmaceutical Co. was acquired by FibroGen (China) Medical Technology Development Co. Ltd. on July 31, 2020 for $2.14 million. The Chinese company was founded in 2019. | 4 years |
| Tricia Stewart | F | - | 3 years | |
| Juan Graham | M | 48 | 3 years | |
| Lu Jin | M | - |
Beijing Falikang Pharmaceutical Co. Ltd.
Beijing Falikang Pharmaceutical Co. Ltd. Pharmaceuticals: MajorHealth Technology Part of FibroGen, Inc., Beijing Falikang Pharmaceutical Co. Ltd. is a pharmaceutical company that manufactures pharmaceutical products. Beijing Falikang Pharmaceutical Co. Ltd. is based in Beijing, China. Beijing Falikang Pharmaceutical Co. was acquired by FibroGen (China) Medical Technology Development Co. Ltd. on July 31, 2020 for $2.14 million. The Chinese company was founded in 2019. | 4 years |
| Xiao Lin | M | - |
Beijing Falikang Pharmaceutical Co. Ltd.
Beijing Falikang Pharmaceutical Co. Ltd. Pharmaceuticals: MajorHealth Technology Part of FibroGen, Inc., Beijing Falikang Pharmaceutical Co. Ltd. is a pharmaceutical company that manufactures pharmaceutical products. Beijing Falikang Pharmaceutical Co. Ltd. is based in Beijing, China. Beijing Falikang Pharmaceutical Co. was acquired by FibroGen (China) Medical Technology Development Co. Ltd. on July 31, 2020 for $2.14 million. The Chinese company was founded in 2019. | 4 years |
| Li De Ke | M | - |
FibroGen (China) Medical Technology Development Co. Ltd.
FibroGen (China) Medical Technology Development Co. Ltd. Pharmaceuticals: MajorHealth Technology Part of FibroGen, Inc., FibroGen (China) Medical Technology Development Co., Ltd. is a biomedical technology company based in Beijing, China. FibroGen () is dedicated to developing new mechanisms of action or "best-in-class" innovative drugs and medical devices to meet the unmet clinical needs of Chinese patients. The Chinese company also provides a platform to report adverse events related to FibroGen roxadustat products. The company was founded in 2011. Christine Chung L. has been the CEO of the company since 2019. | - |
| Joseph Watson | M | - |
Beijing Falikang Pharmaceutical Co. Ltd.
Beijing Falikang Pharmaceutical Co. Ltd. Pharmaceuticals: MajorHealth Technology Part of FibroGen, Inc., Beijing Falikang Pharmaceutical Co. Ltd. is a pharmaceutical company that manufactures pharmaceutical products. Beijing Falikang Pharmaceutical Co. Ltd. is based in Beijing, China. Beijing Falikang Pharmaceutical Co. was acquired by FibroGen (China) Medical Technology Development Co. Ltd. on July 31, 2020 for $2.14 million. The Chinese company was founded in 2019. | 4 years |
| Leanne C. Price | F | - | 25 years | |
| John Hunter | M | 61 | 3 years | |
| Elias Kouchakji | M | 67 | 10 years | |
| David DeLucia | M | - | - | |
| Kirk A. Christoffersen | M | 56 | 4 years | |
| Rahul Rajan Kaushik | M | - | - |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Rory Riggs | M | 71 | 29 years | |
| Thomas Byron Neff | M | 69 | 26 years | |
| Julian N. Stern | M | 99 | 25 years | |
| Thomas Kearns | M | 87 | 26 years | |
| Karen L. Bergman | F | - | - | |
| Enrique Conterno | M | 57 | 3 years | |
| Pat Cotroneo | M | 60 | 21 years | |
| Kalevi Kurkijärvi | M | 72 | 25 years | |
| Patricio Miguel Madero Blasquez | M | 74 | 20 years | |
| Roberto Pedro Rosenkranz | M | 74 | 10 years | |
| Toshinari Tamura | M | 80 | 12 years | |
| David Liu | M | 73 | 8 years | |
| Laura G. Hansen | M | - | 10 years | |
| Percy Carter | M | 53 | 1 years | |
| Seth Porter | M | - | 13 years | |
| Russell Ellison | M | 76 | 2 years | |
| Brain Roberts | M | 49 | 5 years | |
| Gerd Kochendoerfer | M | 56 | 3 years | |
| Michael Martinelli | M | - | 11 years | |
| Greg Mann | M | - | - | |
| Paul J. Frohna | M | - | 1 years | |
| Frank Valone | M | 74 | 8 years | |
| Kin Hung Yu | M | 61 | 12 years | |
| Richard A. Farley | M | - | 6 years | |
| Sarah O'Dowd | F | 74 | 1 years | |
| Claire J. Lockey | F | 71 | 7 years | |
| R. Wayne Frost | M | 69 | - | |
| Mark Eisner | M | 58 | 3 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 48 | 90.57% |
| China | 6 | 11.32% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Christine Chung L.
- Personal Network
